Lv3
208 积分 2025-04-30 加入
1327MO Amivantamab in recurrent/metastatic head & neck squamous cell cancer (HNSCC) after disease progression on checkpoint inhibition and chemotherapy: Results from the phase Ib/II OrigAMI-4 study
8小时前
待确认
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
1个月前
已完结
Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in non-small cell lung cancer treated with third-generation EGFR-TKIs
1个月前
已完结
Targeting c-Met to Improve Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
5个月前
已完结
Amivantamab plus lazertinib vs osimertinib in first-line egfr-mutant advanced non-small cell lung cancer
11个月前
已完结
Evolving roles of MET as a therapeutic target in NSCLC and beyond
1年前
已完结
Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management
1年前
已完结
皖公网安备34019202002308
